scholarly journals Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders, Diffuse Large B-Cell Lymphoma Type, in a Patient with Behçet’s Disease Treated with Cyclosporine A

2020 ◽  
Vol 13 (3) ◽  
pp. 1145-1151 ◽  
Author(s):  
Yuka Urano ◽  
Rintaro Ohe ◽  
Akane Yamada ◽  
Takanobu Kabasawa ◽  
Kazushi Suzuki ◽  
...  

A 40-year-old man had been treated for Behçet’s disease (BD) with cyclosporine A (CsA) for 14 years. He presented multiple lymphadenopathies with fever. Histological examination of surgical biopsy showed other iatrogenic immunodeficiency-associated lymphoproliferative disorders, diffuse large B-cell lymphoma type with positivity for Epstein-Barr virus encoding RNA-1 (EBER-1). <i>BCL2-IgH</i>, <i>BCL6-IgH</i>, and <i>MYC-IgH</i> translocations were not detected. CsA was stopped, and R-CHOP therapy was initiated. However, his lymphoma was chemotherapy resistant and rapidly progressed. To the best of our knowledge, this is the first case of diffuse large B-cell lymphoma that occurred in a BD patient treated with CsA reported in English. Both BD and CsA are associated with the pathogenesis of lymphoma. We also describe extremely rare cases in the form of a literature review.


2008 ◽  
Vol 15 (1) ◽  
pp. 63
Author(s):  
Hyun Jong Hong ◽  
Sang Yeob Lee ◽  
Hye-In Kim ◽  
Jin Yeon Hwang ◽  
Yong Min Jo ◽  
...  


2019 ◽  
Author(s):  
MARÍLIA BULHÕES CALHEIROS ◽  
ALISSON ALIEL VIGANO PUGLIESI ◽  
CAMILLE CONSTANZA CODOGNO POSTIGO CASTRO ◽  
ALOMA GUINAMI SCABORA ◽  
VANI ABREU DE SOUZA FILHO ◽  
...  




2020 ◽  
Vol 112 (5) ◽  
pp. 734-740
Author(s):  
Sandra Sanchez ◽  
Luis Veloza ◽  
Luojun Wang ◽  
Mónica López ◽  
Armando López-Guillermo ◽  
...  


2020 ◽  
Vol 189 (1) ◽  
pp. 97-105 ◽  
Author(s):  
Michael D. Jain ◽  
Ryan Lam ◽  
Zhihui Liu ◽  
Ryan J. Stubbins ◽  
Amrit Kahlon ◽  
...  


2014 ◽  
Vol 12 (5S) ◽  
pp. 797-800 ◽  
Author(s):  
Andrew D. Zelenetz

During his presentation at the NCCN 19th Annual Conference, Dr. Andrew D. Zelenetz reviewed the updates to the 2014 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin’s Lymphomas. Dr. Zelenetz first discussed the updates for diffuse large B-cell lymphoma (DLBCL), focusing primarily on the emergence of MYC-positive DLBCL; the limited role of imaging in early-stage disease; new treatment options; the challenge of tumor heterogeneity; and the impact of cell of origin in the selection of future therapies. Then, on behalf of Dr. Steven Horwitz, Dr. Zelenetz presented the new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia.



Sign in / Sign up

Export Citation Format

Share Document